KPRX
KIORA PHARMACEUTICALS INC
$2.55
-1.92%
$11.3M
No data for this timeframe.
Vol
Market Cap$11.3M
Cap SizeNano Cap
Inst. Holders6 funds
Inst. Value$162.3K
Inst. Activity2 buys / 0 sells
Recent Activity
Jun 10, 2026
Insider
TYLE PRAVEEN was granted 40,000 shares
Director
Jun 10, 2026
Insider
Parsons Erin was granted 25,000 shares
Director
Jun 10, 2026
Insider
Shapiro Aron was granted 25,000 shares
Director
Inst.
VANGUARD GROUP INC — ADD
33,091 shares ($65.2K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
21,200 shares ($41.8K)
May 7, 2026
earnings_calendar
KPRX Q1 2026 Earnings Scheduled — 2026-05-07
Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$12.00 (Sep 2025)
Current $2.55
Low $12.00
Median $12.00
High $12.00
1 analysts
$12.00
$12.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 2, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 28, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 12, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 22, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jul 23, 2024 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.62 ▲ +8.8% | $-0.62 — $-0.62 | -15% YoY | 1 |
| Next Q | $-0.69 ▲ +5.5% | $-0.69 — $-0.69 | -7000% YoY | 1 |
| Current FY | $-2.66 ▲ +8.0% | $-2.66 — $-2.66 | -2% YoY | 1 |
| Next FY | $-1.97 ▲ +8.4% | $-1.97 — $-1.97 | 26% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITADEL ADVISORS LLC | $95.6K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $38.3K | — |
| VANGUARD FIDUCIARY TRUST CO | $25.1K | — |
| MORGAN STANLEY | $2.7K | — |
| Vanguard Global Advisers, LLC | $386.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | TYLE PRAVEEN | A | $0.00 |
| Jun 10, 2026 | Parsons Erin | A | $0.00 |
| Jun 10, 2026 | Shapiro Aron | A | $0.00 |
| Jun 10, 2026 | Hollander David | A | $0.00 |
| Jun 10, 2026 | Stengone Carmine | A | $0.00 |
6 institutional holders with $162.3K total value (84,090 shares) as of 2026-Q1. Top holders: CITADEL, VANGUARD, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 49,533 | $95.6K | 58.9% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 19,861 | $38.3K | 23.6% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 13,030 | $25.1K | 15.5% | — |
| 4 | MORGAN STANLEY | 1,408 | $2.7K | 1.7% | — |
| 5 | Vanguard Global Advisers, LLC | 200 | $386.00 | 0.2% | — |
| 6 | BlackRock, Inc. | 58 | $112.00 | 0.1% | NEAR_EXIT -96.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 20,915 | 33,091 | +58.2% | $65.2K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 12,400 | 21,200 | +71.0% | $41.8K | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 17,644 | 1,364 | -92.3% | $3.8K | 2025-Q3 |
| UBS Group AG | DOUBLED | 2 | 17,644 | +882100.0% | $50.8K | 2025-Q2 |
| BlackRock, Inc. | NEAR_EXIT | 1,606 | 58 | -96.4% | $175.00 | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 354 | 2 | -99.4% | $7.00 | 2024-Q4 |
9 unique insiders with 17 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | TYLE PRAVEEN | Director | AWARD | 40,000 | — | — |
| Jun 10, 2026 | Parsons Erin | Director | AWARD | 25,000 | — | — |
| Jun 10, 2026 | Shapiro Aron | Director | AWARD | 25,000 | — | — |
| Jun 10, 2026 | Hollander David | Director | AWARD | 25,000 | — | — |
| Jun 10, 2026 | Stengone Carmine N. | Director | AWARD | 25,000 | — | — |
| Jun 10, 2026 | Walters-Hoffert Lisa | Director | AWARD | 25,000 | — | — |
| Apr 1, 2026 | Strem Brian M. | President and CEO | TAX W/H | 1,906 | $1.95 | $3.7K |
| Apr 1, 2026 | Tosca Melissa | CFO | TAX W/H | 929 | $1.95 | $1.8K |
| Apr 1, 2026 | Daniels Eric Joseph | Chief Development Officer | TAX W/H | 929 | $1.95 | $1.8K |
| Mar 6, 2026 | Strem Brian M. | President and CEO | AWARD | 16,733 | — | — |
| Mar 6, 2026 | Strem Brian M. | President and CEO | AWARD | 33,467 | — | — |
| Mar 6, 2026 | Daniels Eric Joseph | Chief Development Officer | AWARD | 6,533 | — | — |
| Mar 6, 2026 | Daniels Eric Joseph | Chief Development Officer | AWARD | 13,067 | — | — |
| Mar 6, 2026 | Tosca Melissa | CFO | AWARD | 6,533 | — | — |
| Mar 6, 2026 | Tosca Melissa | CFO | AWARD | 13,067 | — | — |
| Mar 3, 2026 | Strem Brian M. | President and CEO | TAX W/H | 238 | $2.02 | $480.76 |
| Mar 3, 2026 | Daniels Eric Joseph | Chief Development Officer | TAX W/H | 238 | $2.02 | $480.76 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$12.00 mean target (Sep 2025)
$12.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $2.55 |
| Target Low | $12.00 |
| Target Mean | $12.00 |
| Target Median | $12.00 |
| Target High | $12.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.62 | $-0.62 | $-0.62 | -14.8% | +8.8% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.69 | $-0.69 | $-0.69 | -7000.0% | +5.5% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-2.66 | $-2.66 | $-2.66 | -2.3% | +8.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-1.97 | $-1.97 | $-1.97 | 25.9% | +8.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.620 | |
| 7d ago | $-0.680 | +0.060 |
| 30d ago | $-0.680 | +0.060 |
| 60d ago | $-0.690 | +0.070 |
| 90d ago | $-0.690 | +0.070 |
3 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 2, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 28, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 23, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 20, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 27, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 9, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 6, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 24, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 9, 2023 | Maxim Group | MAINTAIN | Buy | Buy |
| May 12, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 24, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Feb 9, 2023 | Maxim Group | UPGRADE | Hold | Buy |
| Feb 8, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Feb 8, 2023 | Ladenburg Thalmann | REITERATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
KPRX Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
Clinical Trial
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Phase Phase 2 — COMPLETED
Mar 23, 2026
earnings_calendar
KPRX Q4 2025 Earnings After Market Close — 2026-03-23